Clinical trial
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
NCT03590054 is registered in ClinicalTrials.gov with Rahul Aggarwal as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
- Lead sponsor
- Rahul Aggarwal
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 20, 2018
- Completion date
- November 30, 2023
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced melanoma, locally advanced solid neoplasm, metastatic head and neck squamous cell carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic urothelial carcinoma, non-small cell lung carcinoma, stage ib lung cancer ajcc v7, stage iii cutaneous melanoma, stage iii cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iii lung cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv cutaneous melanoma, stage iv cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iv lung cancer ajcc v8, stage iv ureter cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8